Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Open accessThe DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Abstract
Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor α (TNF-α). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
TGF-β is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23
Morishima, N., Mizoguchi, I., Takeda, K., Mizuguchi, J., & Yoshimoto, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.140 · Cited by 101
Ciccia, F., Guggino, G., Ferrante, A., Raimondo, S., Bignone, R., Rodolico, V., Peralta, S., van Tok, M. N., Cannizzaro, A., Schinocca, C., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39649 · Cited by 100
Self-citationThe rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
Veale, D. J., McGonagle, D., McInnes, I. B., Krueger, J. G., Ritchlin, C. T., Elewaut, D. S., Kanik, K. S., Hendrikx, T. K., Berstein, G., Hodge, J. A., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/key070 · Cited by 99
Zhang, G., Yu, S., Gran, B., Li, J., Siglienti, I., Chen, X., Calida, D. M., Ventura, E. S., Kamoun, M., & Rostami, A. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4485 · Cited by 96
Genovese, M. C., Durez, P., Richards, H. B., Supronik, J., Dokoupilova, E., Aelion, J. A., Lee, S.-H., Codding, C. E., Kellner, H., Ikawa, T., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130637 · Cited by 96
Brentano, F., Ospelt, C., Stańczyk, J., Gay, R. E., Gay, S., & Kyburz, D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.082081 · Cited by 96
Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis
Hayashi, E., Chiba, A., Tada, K., Haga, K., Kitagaichi, M., Nakajima, S., Kusaoi, M., Sekiya, F., Ogasawara, M., Yamaji, K., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.151133 · Cited by 95
van Tok, M. N., Na, S., Lao, C. R., Alvi, M., Pots, D., van de Sande, M. G. H., Taurog, J. D., Sedgwick, J. D., Baeten, D., & van Duivenvoorde, L. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01550 · Cited by 95
T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis
WANG, C., Liao, Q., Hu, Y., & Zhong, D. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2046 · Cited by 94
Impact of cytokines and T lymphocytes upon osteoclast differentiation and function
Gillespie, M. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2141 · Cited by 94
Toussirot, É., Laheurte, C., Gaugler, B., Gabriel, D., & Saas, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01610 · Cited by 94
Pérez, P., Kwon, Y.-J., Alliende, C., Leyton, L., Aguilera, S., Molina, C., Labra, C. V., Julio, M., Leyton, C., & González, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21265 · Cited by 90
Genovese, M. C., Weinblatt, M. E., Aelion, J. A., Mansikka, H. T., Peloso, P. M. J., Chen, K., Li, Y., Othman, M. I. A., Khatri, A., Khan, N., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40580 · Cited by 82
Zizzo, G., Santis, M. D., Bosello, S. L., Fedele, A. L., Peluso, G., Gremese, E., Tolusso, B., & Ferraccioli, G. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.10.002 · Cited by 75
Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis
Ferreira, M. C., Whibley, N., Mamo, A. J., Siebenlist, U., Chan, Y. R., & Gaffen, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.01389-13 · Cited by 72
IL-17 attenuates the anti-apoptotic effects of GM-CSF in human neutrophils
Dragon, S., Saffar, A. S., Shan, L., & GOUNNI, A. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.04.027 · Cited by 72
The Role of IL-17 and TH17 Cells in the Bone Catabolic Activity of PTH
Pacifici, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00057 · Cited by 69
Oke, V., Brauner, S., Larsson, A. O., Gustafsson, J. T., Zickert, A., Gunnarsson, I., & Svenungsson, E. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1344-7 · Cited by 65
Glatt, S., Taylor, P. C., McInnes, I. B., Schett, G. A., Landewé, R., Baeten, D., Ionescu, L., Strimenopoulou, F., Watling, M. I. L., & Shaw, S. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214943 · Cited by 62
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Mease, P. J., & McInnes, I. B. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0031-5 · Cited by 58
The Interleukin-12 Family: New Players in Transplantation Immunity?
Goriely, S., & Goldman, M. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01651.x · Cited by 56
CCR6+ Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis
Paulissen, S. M. J., van Hamburg, J. P., Davelaar, N., Vroman, H. H., Hazes, J. M. W., de Jong, P. H. P., & Lubberts, E. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0800-5 · Cited by 56
Luo, J., Ming, B., Zhang, C., Deng, X., Li, P., Wei, Z., Xia, Y., Jiang, K., Ye, H., Ma, W., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01755 · Cited by 55
The Role of Interleukin-17A in Psoriatic Disease
Adami, S., Cavani, A., Rossi, F., & Girolomoni, G. (2014) · BioDrugs · doi:10.1007/s40259-014-0098-x · Cited by 52
Role of Subclinical Gut Inflammation in the Pathogenesis of Spondyloarthritis
Rizzo, A. G., Guggino, G., Ferrante, A., & Ciccia, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00063 · Cited by 52
Self-citationAnti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis
Wendling, D., Verhoeven, F., & Prati, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1554053 · Cited by 52
Voigt, A., Esfandiary, L., Wanchoo, A., Glenton, P. A., Donate, A., Craft, W. F., Craft, S. L. M., & Nguyen, C. Q. (2016) · Scientific Reports · doi:10.1038/srep38717 · Cited by 48
Chowdhury, A. C., Chaurasia, S., Mishra, S. K., Aggarwal, A., & Misra, R. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.03.016 · Cited by 48
Reconciling id, ego, and superego within interleukin‐23
Tato, C. M., & Cua, D. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00715.x · Cited by 47
Jana, M., & Pahan, K. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02985.x · Cited by 47
Goldberg, M. R., Nadiv, O., Luknar-Gabor, N., Agar, G., Beer, Y., & Katz, Y. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.004 · Cited by 46
Oral Mucosal Manifestations of AIDS
Greenspan, D., & Greenspan, J. S. (1987) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30717-4 · Cited by 44
Dolcino, M., Lunardi, C., Ottria, A., Tinazzi, E., Patuzzo, G., & Puccetti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115424 · Cited by 43
Guiliano, D. B., Fussell, H., Lenart, I., Tsao, E. H. F., Nesbeth, D., Fletcher, A. J., Campbell, E. C., Yousaf, N., Williams, S., Santos, S. G., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38809 · Cited by 38
A novel treatment for psoriatic arthritis: Janus kinase inhibitors
Chen, M., & Dai, S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000711 · Cited by 37
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Poddubnyy, D., & Sieper, J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00924-5 · Cited by 35
Fleischmann, R. M., Wagner, F., Kivitz, A. J., Mansikka, H. T., Khan, N., Othman, A. A., Khatri, A., Hong, F., Jiang, P., Ruzek, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40319 · Cited by 32 · cited 2×
“Future perspectives to implement the therapeutic options for AS patients include broader anti-inflammatory approaches with multi-cytokine blockade to overcome the inhibition of a single pathway, for example targeting simultaneously TNF-α and IL-17, as in an ongoing study in PsA (149).”
BackgroundGrosskreutz, C. L., Hockey, H., Serra, D. B., & Dryja, T. P. (2015) · Cornea · doi:10.1097/ico.0000000000000627 · Cited by 28
Gan, Y., Zhao, X., He, J., Liu, X., Li, Y., Sun, X., & Li, Z. (2017) · Journal of Immunology Research · doi:10.1155/2017/4768408 · Cited by 24
Ustekinumab in psoriatic arthritis and related phenotypes
Dobbin-Sears, I., Roberts, J., O’Rielly, D. D., & Rahman, P. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318781760 · Cited by 23
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Ly, K., Beck, K. M., Smith, M. R., Orbai, A., & Liao, W. J. (2019) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s161453 · Cited by 23
A Review of the Use of Secukinumab for Psoriatic Arthritis
Patel, N., Vera, N., Shealy, E. R., Wetzel, M. E., & Feldman, S. R. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0076-0 · Cited by 22
Nash, P. T., Kirkham, B. W., Okada, M., Rahman, P., Combe, B. G., Adams, D., KERR, L.-A., Lee, C., Shuler, C., & Genovese, M. C. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.1576 · Cited by 14
Mori, G., Cantatore, F. P., Brunetti, G., Oranger, A., Colaianni, G., Quarta, L., Corrado, A., Colucci, S. C., & Grano, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.013 · Cited by 11
Cited by
The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
Cutolo, M., Campitiello, R., Gotelli, E., & Soldano, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867260 · Cited by 631
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Azuaga, A. B., Ramírez, J., & Cañete, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054901 · Cited by 190
“On the other hand, a variety of innate cells, including MAIT, ILC3, iNKT, and γδ T cells, can produce IL-17 in an IL-23-independent manner [146,147], implicating them in disease pathogenesis.”
BackgroundGe, L., Liu, S., Li, S., Yang, J., Hu, G., Xu, C., & Song, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016578 · Cited by 187
Metadata
- Authors
- Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-22
- Volume
- 12
- Pages
- 637829-637829
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3132820286
- Cited by
- 360
- References
- 244
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.